A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-02. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
An acidic N-terminus transactivation domain (TAD), including activation domains 1 and 2 (AD1: residues 1–42; AD2: residues 43–63), which regulate transcription of several pro-apoptotic genes. A proline-rich domain (residues 64–92), involved in apoptotic function and nuclear export via MAPK signaling. A central DNA-binding domain (DBD; residues 102–292), containing a zinc atom and multiple arginine residues, essential for sequence-specific DNA interaction and co-repressor binding such as LMO3. A nuclear localization sequence (NLS; residues 316–325), required for nuclear import. A homo-oligomerization domain (OD; residues 307–355), which mediates tetramerization—essential for p53 activity in vivo. A C-terminal regulatory domain (residues 356–393), which modulates the DNA-binding activity of the central domain. Most cancer-associated mutations in TP53 occur in the DBD, impairing DNA binding and transcriptional activation. These are typically recessive loss-of-function mutations. By contrast, mutations in the OD can exert dominant negative effects by forming inactive complexes with wild-type p53. Wild-type p53 is a labile protein containing both folded and intrinsically disordered regions that act synergistically. Although designated as a 53 kDa protein by SDS-PAGE, the actual molecular weight of p53α is 43.7 kDa. The discrepancy is due to its high proline content, which slows electrophoretic migration.
== Distribution == Geography cones are common. They occur in the Red Sea and in the Indian Ocean off Chagos, Réunion, Madagascar, Mauritius, Mozambique and Tanzania. They are indigenous to the reefs of the Indo-Pacific region, except for Hawaii, and off Australia (the Northern Territory, Queensland, Western Australia). Since the distribution of C. geographus can largely be explained by the temperature of its habitat, alterations due to climate change are predicted to impact its distribution in the following decades. The seas around Southeast Asia are in parts predicted to have a higher suitability by 2090, while parts of Australia and Africa's eastern coast could become less suitable.
== Further reading == Kropotkin, Peter Alexeivitch; Bealby, John Thomas (1911). "Don Cossacks, Territory of the" . Encyclopædia Britannica. Vol. 8 (11th ed.). p. 412. Peter Holquist, "'Conduct Merciless Mass Terror': Decossackization on the Don, 1919," Cahiers du Monde russe, vol. 38, no. 1/2(Jan.-June 1997), pp. 127–162. In JSTOR Noël Bonneuil, Elena Fursa. 2020. "Nuptiality to regulate the commons? The case of the Don Cossacks (South Russia), 1867–1916." Oxford Economic Papers
At certain times in the geological past, reef-building organisms similar to corals were very abundant. Like modern corals, these ancient organisms built reefs, some of which ended as great structures in sedimentary rocks. Fossils of fellow reef-dwellers algae, sponges, and the remains of many echinoids, brachiopods, bivalves, gastropods, and trilobites appear along with coral fossils. This makes some corals useful index fossils. Coral fossils are not restricted to reef remnants, and many solitary fossils are found elsewhere, such as Cyclocyathus, which occurs in England's Gault clay formation.
Tavapadon, sold under the brand name Juvmo, is a dopamine receptor agonist used for the treatment of Parkinson's disease. It is taken by mouth. Tavapadon was approved for medical use in the United States in September 2026.
Sources: en.wikipedia.org
In 2020, Schmitt was among 17 Republican attorneys general who joined Texas attorney general Ken Paxton in suing Georgia, Michigan, Wisconsin, and Pennsylvania to invalidate their electoral votes in the 2020 United States presidential election. The suit claimed the four states' presidential vote tallies were unconstitutional; no evidence supported these claims and the arguments had already been rejected in other state and federal courts. On December 11, 2020, the Supreme Court rejected the suit in an unsigned opinion.
1 At the state elections on 15 February 1936, James Kenneally lost his East Perth seat to an Independent Labor candidate, Thomas Hughes. Kenneally and another candidate contested the poll citing Hughes's status as an undischarged bankrupt at the time of the poll (meaning that he was not eligible to stand), and a fresh by-election was called for 9 May, which Hughes won. On 13 May, Kenneally resigned from the Collier Ministry. Bert Hawke replaced him in the Executive Council and in two of his portfolios, whilst Millington and Wise reshuffled portfolios, in part to unite Works and Water Supplies under one minister. 2 Willcock assumed all of Collier's portfolios from 20 August 1936 until 27 August 1936 whilst Caucus selected a new Cabinet.
==== Use of booby-trapped devices ==== Experts warned the 2024 Lebanon electronic device attacks potentially violated international humanitarian law. Josep Borrell, the European Union's High Representative for Foreign Affairs and Security Policy, questioned the legality of the pager attacks due to their high collateral damage among civilians, including the deaths of children. Jeanine Hennis-Plasschaert, the United Nations Special Coordinator for Lebanon, also raised concerns that the attacks were illegal. Belgian deputy prime minister Petra De Sutter went further, calling it a "terror attack". Volker Turk, the UN human rights chief, stated, "International humanitarian law prohibits the use of booby-trap devices in the form of apparently harmless portable objects". Booby traps are mostly outlawed under the Protocol on Mines, Booby-Traps and Other Devices ("Amended Protocol II") of the Convention on Certain Conventional Weapons, to which Israel is a party. Article 7, paragraph 2 of Amended Protocol II prohibits the use of "booby-traps or other devices in the form of apparently harmless portable objects which are specifically designed and constructed to contain explosive material." The rules of engagement of some countries, such as the United Kingdom, also ban explosive devices disguised as harmless items.
"Particles of dust or smoke in the atmosphere are essential for precipitation. These particles, called 'condensation nuclei,' provide a surface for water vapor to condense upon. This helps water droplets gather together and become large enough to fall to the earth which might affect the quality of our water if not for filters." Aerosol Ash (chemistry) Black carbon Carbon, basic component of ashes Carbon black Charcoal, carbon residue after heating wood mainly used as traditional fuel Cinereous, consisting of ashes, ash-colored or ash-like Coal, consisting of carbon as ash, and ash can be converted into coal Construction waste Dust | Fugitive dust Potash, a term for many useful potassium salts that traditionally derived from plant ashes, but today are typically mined from underground deposits
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.